Xencor Inc receives Investment Bank Analyst Rating Update
- ByInvesting.com-
Symbol | Exchange | Currency |
|---|
Investing.com - Xencor Inc (NASDAQ: XNCR) reported first quarter EPS of $-1.02, $0.36 worse than the analyst estimate of $-0.66. Revenue for the quarter came in at $18.9M versus...
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today...
Biotechnology stocks represent companies that research, develop or market healthcare-related therapies or products. They typically use living organisms, biological systems, or...
United Therapeutics (NASDAQ:UTHR) UTHR announced that the FDA has issued a complete response letter to its new drug application (“NDA”) for its drug device combination...
United Therapeutics (NASDAQ:UTHR) UTHR announced that the FDA has issued a complete response letter to its new drug application (“NDA”) for its drug device combination...
Xencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies and cytokine therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs. It uses protein engineering capabilities to enable its understanding of protein structures and interactions and to design technologies and XmAb drug candidates with improved properties. It is advancing its XmAb drug candidates into clinical-stage development. It is focused on the Fc domain, which is part of an antibody that interacts with various segments of the immune system and controls antibody structural architecture. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Vudalimab, XmAb104, XmAb564, XmAb819, XmAb808, Plamotamab, Obexelimab, Sotrovimab, XmAb306/RG6323, and others.
| Average | 42.92 (+57.52% Upside) |
| High | 59.00 |
| Low | 27.00 |
| Price | 27.25 |
| No. of Analysts | 13 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
| Technical Indicators | Strong Sell | Sell | Buy | Sell | Strong Sell |
| Summary | Strong Sell | Strong Sell | Neutral | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 125.43 | 126.00 | 123.29 | +1.08 | +0.87% | 25.17M | NASDAQ | |||
| 10.28 | 10.40 | 9.84 | +0.50 | +5.11% | 20.39M | NYSE | |||
| 37.87 | 39.41 | 37.75 | 0.00 | 0.00% | 0.00 | NYSE | |||
| 7.12 | 7.38 | 7.07 | -0.16 | -2.20% | 716.99K | NYSE | |||
| 26.25 | 26.45 | 25.21 | +0.89 | +3.51% | 850.27K | NASDAQ | |||
| 27.60 | 27.66 | 26.67 | +0.75 | +2.79% | 922.76K | NYSE | |||
| 0.514 | 0.543 | 0.48 | -0.029 | -5.25% | 126.43K | NASDAQ | |||
| 2.43 | 2.54 | 2.43 | -0.07 | -2.80% | 921.00 | OTC Markets | |||
| 0.94 | 0.94 | 0.94 | -0.00 | -0.15% | 12.46K | OTC Markets | |||
| 4.82 | 4.82 | 4.82 | 0.00 | 0.00% | 0.00 | OTC Markets | |||
| 3.00 | 3.00 | 3.00 | 0.00 | 0.00% | 0.00 | OTC Markets | |||
| 5.00 | 5.00 | 5.00 | 0.00 | 0.00% | 0.00 | OTC Markets | |||
| 18.63 | 18.69 | 18.615 | +0.160 | +0.87% | 24.57K | OTC Markets | |||
| 38.45 | 38.75 | 38.32 | +0.25 | +0.65% | 15.16K | OTC Markets | |||
| 1.86 | 1.90 | 1.82 | -0.50 | -21.19% | 51.35M | NASDAQ |